Denosumab
Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor κ-B ligand (RANKL), a key Signaling molecule in osteoclast differentiation, activation, and survival.
Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor κ-B ligand (RANKL), a key Signaling molecule in osteoclast differentiation, activation, and survival. By binding RANKL, denosumab prevents its interaction with the RANK receptor on osteoclast precursors and mature osteoclasts. This suppresses bone resorption and reduces bone remodeling, increasing bone mineral density and lowering fracture risk in appropriately selected patients.
Denosumab is used primarily in the management of osteoporosis, including osteoporosis in postmenopausal women and other populations at increased fracture risk. It is also used in some oncology settings to reduce skeletal complications associated with bone involvement by malignancy. Because its effect is reversible and does not persist as a long-term skeletal residue in the manner of many bisphosphonates, interruption or discontinuation requires careful clinical planning. Inadequate follow-up after a missed or discontinued dose can permit rapid recovery of bone turnover and loss of antiresorptive protection. Clinically relevant safety considerations include hypocalcemia, infections, dermatologic reactions, atypical femoral fractures, and medication-related osteonecrosis of the jaw (MRONJ), particularly in the context of invasive dental disease or cumulative antiresorptive exposure.
Denosumab acts on the RANK–RANKL–osteoprotegerin pathway, which regulates bone remodeling and links osteoblast-lineage cells to osteoclast activity. It is therefore pharmacologically distinct from anabolic agents such as romosozumab and parathyroid hormone analogues, and from bisphosphonates such as alendronic acid and zoledronate. In treatment sequences, transitions among these therapies may influence bone density, fracture protection, and the risk of excessive suppression of bone turnover. Its potential combination with immune checkpoint Therapy, including pembrolizumab, has also been investigated in advanced Cancer.
Where the papers sit
10 papers from the last 6 months study denosumab directly · updated from PubMed 13 Nov 2026
Study type 1 clinical trial · 6 observational · 3 human data
Themes one subject · 2 new directions
Those 10 are all about one subject.
-
Clinical Osteoporosis Management
Osteoporosis management is moving toward longer-term, individualized antiresorptive care. Discontinuation patterns, adherence interventions, bone mineral density, and fracture risk recur as practical endpoints, while sequential romosozumab–denosumab therapy is being assessed for severe disease. Long-term safety remains central, including medication-related osteonecrosis of the jaw and cardiovascular outcomes with romosozumab. The literature also flags denosumab interference in serum protein electrophoresis and exploratory use with pembrolizumab in renal-cell carcinoma.
Denosumab is also a diagnostic interferent in monoclonal-protein testing
The serum protein electrophoresis study of denosumab found that, beyond its therapeutic use, the antibody migrates in the gamma region and can complicate interpretation of serum protein electrophoresis and immunofixation in patients with multiple myeloma; mass spectrometry can distinguish it from endogenous M-proteins, adding denosumab recognition to monoclonal-protein assessment 42847316Oct.
Denosumab is being developed as an immunotherapy-potentiating partner rather than solely as bone-directed treatment
The phase 2 study of pembrolizumab plus denosumab in pretreated advanced clear-cell renal-cell carcinoma assigned denosumab a role as an adjunct intended to inhibit RANKL signaling and potentially enhance immune-checkpoint inhibition, extending its use from bone disease management to combination anticancer immunotherapy 42336709Jun.
Papers
The 10 papers from the last 6 months that study denosumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Clinical Osteoporosis Management (10)
- Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study. Archives of osteoporosis · 12 Nov 2026 PMID 43018839
- Baseline characteristics and bone mineral density changes associated with lower fracture risk in osteoporosis: a retrospective cohort study. Rheumatology international · 16 Oct 2026 PMID 42888324
- Investigating Denosumab Interference in Serum Protein Electrophoresis. The journal of applied laboratory medicine · 8 Oct 2026 PMID 42847316
- Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. Yonsei medical journal · 24 Aug 2026 PMID 42634293
- Long-term effects of denosumab: a 10-year single-center retrospective study. Archives of osteoporosis · 19 Aug 2026 PMID 42616205
- Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. Archives of osteoporosis · 14 Aug 2026 PMID 42599329
- Impact of clinical pharmacist-led interventions on denosumab adherence. Archives of osteoporosis · 6 Aug 2026 PMID 42560392
- Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study. Clinical oral investigations · 12 Jul 2026 PMID 42437851
- Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified tissue international · 9 Jul 2026 PMID 42423749
- Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical genitourinary cancer · 23 Jun 2026 PMID 42336709
By study type
Clinical trials (1)
- Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical genitourinary cancer · 23 Jun 2026 PMID 42336709
Observational studies and case reports (6)
- Baseline characteristics and bone mineral density changes associated with lower fracture risk in osteoporosis: a retrospective cohort study. Rheumatology international · 16 Oct 2026 PMID 42888324
- Investigating Denosumab Interference in Serum Protein Electrophoresis. The journal of applied laboratory medicine · 8 Oct 2026 PMID 42847316
- Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. Yonsei medical journal · 24 Aug 2026 PMID 42634293
- Long-term effects of denosumab: a 10-year single-center retrospective study. Archives of osteoporosis · 19 Aug 2026 PMID 42616205
- Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. Archives of osteoporosis · 14 Aug 2026 PMID 42599329
- Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study. Clinical oral investigations · 12 Jul 2026 PMID 42437851
Human data, design not indexed (3)
- Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study. Archives of osteoporosis · 12 Nov 2026 PMID 43018839
- Impact of clinical pharmacist-led interventions on denosumab adherence. Archives of osteoporosis · 6 Aug 2026 PMID 42560392
- Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified tissue international · 9 Jul 2026 PMID 42423749
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Drafted by language models from published abstracts; not medical advice.